LWANC
FLNA

Laurel Wealth Advisors (North Carolina)’s Filana Therapeutics FLNA Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17
Closed -$34 – 549
2025
Q4 		$34 Buy
+17
New +$54 ﹤0.01% 699
2025
Q2 		– Sell
-17
Closed -$26 – 571
2025
Q1 		$26 Hold
17
– – ﹤0.01% 694
2024
Q4 		$41 Hold
17
– – ﹤0.01% 727
2024
Q3 		$501 Buy
+17
New +$392 ﹤0.01% 656

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s FLNA Position: Q1 2026 in Review

Laurel Wealth Advisors (North Carolina) sold out of Filana Therapeutics (FLNA) in Q1 2026, closing a stake of 17 shares — an estimated $34 sold.

Laurel Wealth Advisors (North Carolina) first reported a position in FLNA in Q3 2024 and held it in 4 quarters. The position peaked at $501 in Q3 2024. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Laurel Wealth Advisors (North Carolina) reported no remaining Filana Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 17 Filana Therapeutics shares in Q1 2026, an estimated $34.
  • Laurel Wealth Advisors (North Carolina) first reported a position in Filana Therapeutics in Q3 2024 and held it in 4 quarters.
  • Laurel Wealth Advisors (North Carolina)'s Filana Therapeutics position peaked at $501 in Q3 2024.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q1 2026, filed 13 May 2026.